ENTERA BIO

What ENTERA BIO does

Entera Bio Ltd. is a clinical-stage biopharmaceutical company listed on NASDAQ (ENTX) and headquartered at Hadassah Bio Park in Jerusalem, Israel, that develops oral formulations of peptide and protein replacement therapies. Its proprietary N-Tab® delivery platform combines permeation enhancers and protease inhibitors to stabilize large-molecule (≥4kD, hydrophilic) peptides in the gastrointestinal tract and promote absorption as oral tablets, addressing the historical limitation that such therapeutics required injection. The company is pre-revenue, with no approved products, and operates with a leadership team of approximately 12 named executives and a headcount in the 11–50 range.

The pipeline is built entirely on the N-Tab® platform and includes the lead candidate EB613 (oral PTH(1-34)/teriparatide) for postmenopausal osteoporosis, EB612 (oral PTH for hypoparathyroidism, co-developed with OPKO Health on a 50/50 basis), EB618 (oral oxyntomodulin, a GLP-1/glucagon dual agonist for obesity and metabolic disease, OPKO partnership), and an oral GLP-2 candidate for short bowel syndrome (OPKO partnership), plus an investigator-sponsored study of EB613 in stress fracture healing. The primary addressable market is postmenopausal women with osteoporosis — Entera cites ~200 million women affected globally and ~15 million diagnosed in the U.S., with a 1-in-3 lifetime fracture risk in women over 50 — where less than 10% of treated patients currently receive injectable anabolics such as Forteo, Tymlos, and Evenity.

Entera's commercial model is pre-commercial and oriented around KOL engagement, peer-reviewed publications (JBMR Phase 2 paper), and congress presence (ENDO, ASBMR, WCO-IOF-ESCEO, NAMS), with planned future distribution through a specialty sales force calling on endocrinologists, rheumatologists, gynecologists, and bone-health specialists supplemented by specialty pharmacy fulfillment and payer engagement. Future revenue is expected to come from product sales (EB613), licensing/royalty income and milestones from OPKO-co-developed programs, and capital raises; the company currently relies on equity financings, most recently a $10 million private placement led by BVF Partners L.P. in April 2026 (up to ~$24.5M with full warrant exercise), against $11.9 million of cash as of March 31, 2026, a Q1 2026 net loss of $3.5 million, and an FY2025 net loss of $11.4 million.

Name

ENTERA BIO

Legal name

Entera Bio Ltd.

Website

https://enterabio.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies using its proprietary N-Tab® platform, with lead candidate EB613 (oral PTH(1-34)) advancing into a 750-patient Phase 3 trial for postmenopausal osteoporosis.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Oral Peptide Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Oral peptide delivery
• Osteoporosis therapeutics
• Biopharmaceutical development
• Oral teriparatide
• N-Tab platform

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Future product sales (EB613): Planned primary revenue stream upon regulatory approval: commercialization of EB613 (oral teriparatide / PTH(1-34)) for postmenopausal osteoporosis as a once-daily oral tablet. Pre-revenue at present; economics not yet defined.
2. Future licensing / partnership royalties (EB612, EB618/OXM, GLP-2): Co-development and potential licensing/commercialization of additional pipeline candidates with strategic partners (notably the 50/50 OPKO Health collaboration covering EB612, EB618/OXM, and GLP-2 for short bowel syndrome). Revenue mechanics expected to include milestone payments and royalties/equity sharing.
3. Capital raises (pre-revenue financing): Current funding model relies on equity financings. A $10 million private placement led by BVF Partners was completed in April 2026, with up to approximately $24.5 million of additional gross proceeds available if warrants are exercised in full.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Entera Bio is a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies using its proprietary N-Tab® platform, which enables formulation of large-molecule peptides (≥4kD, hydrophilic) as small oral tablets instead of injections. Its lead clinical asset EB613 is a once-daily oral tablet formulation of PTH(1-34)/teriparatide in Phase 3 development for postmenopausal osteoporosis, supported by additional pipeline programs (EB612 for hypoparathyroidism, OXM for obesity, GLP-2 for short bowel syndrome) co-developed with OPKO Health. The company is pre-commercial and pre-revenue, financing its development through equity capital.

Product overview

Entera Bio's offering is a platform-plus-pipeline architecture centered on the proprietary N-Tab® oral peptide delivery platform, from which all clinical candidates are derived. The lead asset EB613 (oral PTH(1-34) for postmenopausal osteoporosis) is the most advanced, supported by additional pipeline programs including EB612 (hypoparathyroidism), the EB613 Stress Fractures investigator-sponsored program, and partnered OXM (oxyntomodulin) and GLP-2 programs developed with OPKO Health. Each named product in the portfolio is an application of the same N-Tab® platform technology, with EB613 carrying the portfolio commercially and clinically.

Differentiator

Problem solved

Functional benefit

Products and services

• EB613 (oral PTH(1-34) / oral teriparatide) First-in-class, single-tablet oral formulation of PTH(1-34) (teriparatide) in Phase 3 development for the treatment of postmenopausal osteoporosis in women at high risk of fragility fracture. The most advanced program in Entera's pipeline and the primary commercial asset; FDA accepted the registrational Phase 3 protocol in approximately 750 postmenopausal women with 12-month total hip BMD as the primary endpoint, supporting a potential NDA submission, with topline data anticipated in H2 2028.
• EB612 (oral PTH for hypoparathyroidism) Oral tablet formulation of PTH(1-34) being developed as the first oral PTH(1-34) peptide replacement therapy for patients with hypoparathyroidism (a rare endocrine disorder). Co-developed 50/50 with OPKO Health, with planned advancement toward an IND submission; targets an estimated 200,000+ hypoparathyroidism patients worldwide who currently rely on multiple daily injectable PTH.
• OXM Program (oral oxyntomodulin) Oral peptide candidate co-developed with OPKO Health that leverages the N-Tab® platform to deliver oxyntomodulin (a dual GLP-1/glucagon peptide) as an oral tablet for the treatment of obesity and broader metabolic disease. Targeted at the ~73% of U.S. adults who are overweight or obese, and designed to provide an oral peptide option in a category dominated by injectable therapies.
• GLP-2 Program (oral glucagon-like peptide-2) Oral glucagon-like peptide-2 (GLP-2) candidate co-developed with OPKO Health on the N-Tab® platform, intended for rare metabolic and gastrointestinal indications including short bowel syndrome (SBS) in patients with intestinal failure and parenteral support dependence. Designed to provide the first oral GLP-2 therapy in this indication.
• EB613 Stress Fractures (Investigator-Sponsored Program) Investigator-Sponsored Trial (IST) program exploring EB613 (oral PTH(1-34)) in stress fracture healing — an adjacent/early-stage opportunity that expands the potential indications for the lead N-Tab®-based candidate beyond postmenopausal osteoporosis.

Quantifiable outcome

• Patient preference: 14 of 15 patients preferred a single-tablet regimen and 15 of 15 preferred oral over injection in a stated survey
• +4 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered flagship and minor.

• OPKO HealthflagshipStrategic or Co-development Partner50/50 co-development partnership covering three pipeline programs: EB612 (oral long-acting PTH for hypoparathyroidism), EB618 / OXM (oral oxyntomodulin, a GLP-1/glucagon dual agonist for obesity and metabolic disease), and an oral GLP-2 analog for short bowel syndrome (SBS). OPKO is a key strategic partner that defines a large portion of Entera's non-EB613 pipeline and future commercialization pathways for those assets.
• Greenberg TraurigminorOthersExternal legal counsel referenced in connection with the April 2026 BVF Partners-led financing and corporate transactions. Not a strategic operating partnership.
• FNIH-ASBMR-SABRE teamminorStrategic or Co-development PartnerRegulatory and scientific collaboration between the Foundation for the National Institutes of Health (FNIH), the American Society for Bone and Mineral Research (ASBMR), and the SABRE team. Entera Bio references participation in this collaboration to support the regulatory and biomarker pathway for EB613 in osteoporosis.

Scale indicators15 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Eli Lilly: Originating developer and marketer of Forteo (teriparatide), the injectable PTH(1-34) that EB613 is designed to replace orally. Also pursuing oral GLP-1 and other oral peptide programs that compete for the same N-Tab® application space.
• Novo Nordisk: Broad incumbent with Rybelsus (oral semaglutide), the first approved oral peptide therapeutic and a direct platform-level parallel to Entera's N-Tab® approach. Validates the oral peptide market opportunity but also represents a vastly resourced competitor in adjacent indications.
• Amgen: Markets Evenity (romosozumab) and Prolia (denosumab), the two dominant non-PTH anabolic and antiresorptive therapies in osteoporosis. Represents the standard-of-care competitive backdrop EB613 will need to displace or expand the market against.

Direct peers

• Radius Health: Developed and initially commercialized Tymlos (abaloparatide), an injectable PTH analog directly competing with Forteo in the same osteoporosis anabolic market EB613 targets. Most direct head-to-head competitive parallel for an anabolic osteoporosis therapy.
• Rani Therapeutics: Clinical-stage company developing an oral (robotic pill) delivery platform for biologics and peptides. Closest direct platform peer to N-Tab®, focused on the same problem of making injectable peptides orally bioavailable.
• Crinetics Pharmaceuticals: Clinical-stage company developing oral peptide therapeutics (e.g., paltusotine for acromegaly) using a non-invasive oral small-molecule approach. Most relevant pure-play oral peptide peer with a similar development-stage profile.
• Zealand Pharma: Clinical and commercial-stage peptide engineering company with multiple peptide programs including oral dasiglucagon. Comparable as an oral peptide platform company with metabolic/endocrine focus similar to Entera's pipeline.

Emerging players

• Ascendis Pharma: Late-stage company applying its TransCon technology to long-acting peptide prodrugs (e.g., lonapegsomatropin, TransCon PTH). Relevant comparable for long-acting peptide/protein delivery approaches targeting adjacent endocrine indications.
• Provention Bio (Sanofi): Developed Tzield (teplizumab), a peptide-based biologic for type 1 diabetes, now part of Sanofi. Comparable as a peptide/protein therapeutic developer in metabolic and autoimmune disease that was acquired by a large-cap pharma partner.

Others

• OPKO Health: 50/50 strategic partner on Entera's EB612, oral OXM, and GLP-2 programs. While not a direct competitor, OPKO is the most strategically entangled counterparty and a key determinant of the partnered pipeline's trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=2z6oOgwAWmg
• LinkedInlinkedin.com/company/entera-bio-ltd-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENTERA BIO